首页 文献索引 SCI期刊 AI助手
期刊目录筛选

期刊名:Esmo open

缩写:

ISSN:N/A

e-ISSN:2059-7029

IF/分区:8.3/Q1

文章目录 更多期刊信息

共收录本刊相关文章索引2013
Clinical Trial Case Reports Meta-Analysis RCT Review Systematic Review
Classical Article Case Reports Clinical Study Clinical Trial Clinical Trial Protocol Comment Comparative Study Editorial Guideline Letter Meta-Analysis Multicenter Study Observational Study Randomized Controlled Trial Review Systematic Review
Y Yao,Z Yu,Y Ma et al. Y Yao et al.
Background: Kinase gene fusions are strong driver mutations in neoplasia; however, kinase intergenic-breakpoint rearrangements (IGRs) confound the detection of such fusions and of targeted treatments. We aim to provide an...
J Tabernero,F Andre,J-Y Blay et al. J Tabernero et al.
Background: The programmed death-ligand 1 inhibitor atezolizumab had shown clinical activity against several advanced malignancies. Patients and methods: ...
C Zhou,J O&#x;Connor,A Backen et al. C Zhou et al.
Background: Vascular endothelial growth factor inhibitors (VEGFi) are compromised by a lack of validated biomarkers. Previously we showed that changes in the concentration of plasma Tie2 (pTie2) was a response biomarker f...
L Paz-Ares,Y Chen,N Reinmuth et al. L Paz-Ares et al.
Background: In the phase III CASPIAN study, first-line durvalumab in combination with etoposide plus either cisplatin or carboplatin (EP) significantly improved overall survival (OS) versus EP alone in extensive-stage sma...
A Preda,T Ciuleanu,P Kubelac et al. A Preda et al.
Background: The evolution of COVID-19 is a controversial topic in cancer patients. They have been designated by international organizations as a vulnerable population at greater risk for contracting SARS-CoV-2 and having ...
V Guarneri,G Griguolo,F Miglietta et al. V Guarneri et al.
Background: Studies testing the addition of lapatinib to neoadjuvant trastuzumab + chemotherapy reported an increase in pathologic complete response (pCR), with, nevertheless, discordant results in terms of survival, main...
W C Tan,R Kanesvaran W C Tan
Optimizing treatment of genitourinary cancers in the early-stage setting continues to remain an area of need, given that the development of distant metastases is often the life-limiting factor in the natural history of these cancers. The us...